Latest Breaking News On - Naefk basile cancer institute - Page 1 : comparemela.com

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder

Agios Pharmaceuticals Inc.’s stock soared 19.6% early Wednesday, after the biotech announced positive results from a Phase 3 trial of a treatment for a rare.

Agios Pharma (AGIO) Reports Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

03.01.2024 - –Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin . Seite 1

Lebanese professor Ali Taher recognized among top 50 researchers worldwide

Lebanon News, Breaking News | Taher is primarily focusing on the prevention and management of Thalassemia patients